MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1 - Li, Hui; Li, Chia-Wei; Li, Xiaoqiang; Ding, Qingqing; Guo, Lei; Liu, Shuang; Liu, Chunxiao; Lai, Chien-Chen; Hsu, Jung-Mao; Dong, Qiongzhu; Xia, Weiya; Hsu, Jennifer L.; et al. (Gastroenterology (New York, N.Y. 1943), 2019)
Keywords: Animals; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; B7-H1 Antigen - metabolism; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - enzymology; Carcinoma, Hepatocellular - immunology; Cell Line, Tumor; Down-Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta - metabolism; Granzymes - metabolism; Hepatocellular Carcinoma; Imidazoles - pharmacology; Imidazoles - therapeutic use; Liver Neoplasms - drug therapy; Liver Neoplasms - enzymology; Liver Neoplasms - immunology; Male; Mice; Phosphorylation; Programmed Cell Death Ligand 1; Proto-Oncogene Proteins c-met - antagonists & inhibitors; Proto-Oncogene Proteins c-met - metabolism; Pyrrolidinones - pharmacology; Pyrrolidinones - therapeutic use; Quinolines - pharmacology; Quinolines - therapeutic use; TNF Receptor-Associated Factor 6 - immunology; TNF Receptor-Associated Factor 6 - metabolism; Triazines - pharmacology; Triazines - therapeutic use; Tumor Escape - drug effects; Tumor Necrosis Factor Receptor-Associated Factor 6; Ubiquitination; GSK3B; Y56F; Glycogen Synthase Kinase 3; HCC; Tumor Necrosis Factor Receptor-Associated Factor 6; p; shRNA; TRAF6; Y56; PD1; PDL1; WT; Programmed Cell Death Ligand 1; Hepatocellular Carcinoma